Mario Sznol

24PUBLICATIONS
168CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|May 06, 2026
Non-invasive profiling of the tumour microenvironment with spatial ecotypes.

|Apr 09, 2026
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Jose Luis Perez-Gracia, Begoña Mellado, Aaron Richard Hansen

|Feb 13, 2026
Ex Vivo Expansion of Melanoma Tumor-Infiltrating Lymphocytes Leads to a Dominant Exhausted T-cell Population with a Lack of Memory Markers.

Gianfilippo Coppola, Samuel Kerr, Pei-Chun Cha

|Aug 30, 2025
LZTR1 is a melanoma oncogene that promotes invasion and suppresses apoptosis.

Antonella Bacchiocchi, Michael Mak, Zerin Mahzabin Khan

|Mar 06, 2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.

Sarah A Weiss, Dijana Djureinovic, Wei Wei

|Feb 03, 2025
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.

Eva Munoz-Couselo, Ainara Soria Rivas, Shahneen Sandhu

Pageof 4

Frequent Collaborators

6 joint publications

Ruth Halaban

5 joint publications

Aaron M Newman

5 joint publications

Harriet M Kluger

4 joint publications

Sarah A Weiss